Our study constitutes the first proof of concept showing the feasibility of conducting gene editing in primary FA CD34+ cells as a future therapeutic approach for the treatment of bone marrow failure syndromes such as FA, characterized by evident functional defects at the HSPC level. The gene discussed is CD34; the disease is Friedreich ataxia.